Overview

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects

Status:
Completed
Trial end date:
2021-05-15
Target enrollment:
Participant gender:
Summary
This study is to evaluate to compare the pharmacokinetics, safety, tolerability, and immunogenicity of two formulations of SB5 in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Samsung Bioepis Co., Ltd.
Treatments:
Adalimumab